Scientists have engineered smart nanoparticles that can both illuminate hidden glioblastoma cells during surgery and destroy microscopic cancer left behind afterward, a dual-action approach that could transform treatment for one of the most aggressive brain cancers. In mouse studies, the therapy prevented tumor recurrence and achieved 100% survival at 60 days, though it has not yet been tested in humans.
Glioblastoma is notoriously difficult to treat because its finger-like projections invade surrounding brain tissue, making complete surgical removal nearly impossible. Even when surgeons remove the visible tumor, microscopic cancer cells often remain, leading to recurrence and a median survival of just over a year. The new nanoparticles, described in a study released by ScienceDaily, aim to address both problems simultaneously.
The nanoparticles are designed to home in on glioblastoma cells and emit a fluorescent signal that makes them visible under special imaging during surgery. This allows surgeons to see and remove not only the main tumor but also small satellite lesions that would otherwise be missed. After surgery, the same nanoparticles are activated by a near-infrared light source to generate heat, destroying any remaining cancer cells that were too small to be seen or removed.
In experiments with mice bearing glioblastoma tumors, the treatment led to complete eradication of residual disease and prevented recurrence for the duration of the 60-day observation period. All treated animals survived, whereas control groups succumbed to tumor regrowth. The researchers noted that the dual functionality — imaging and therapy — is achieved with a single nanoparticle formulation, simplifying the approach and potentially reducing side effects.
The study highlights the promise of theranostics, a strategy that combines diagnostic imaging with targeted therapy. By using nanoparticles that can both reveal and treat cancer, the approach could improve surgical precision and reduce the need for additional treatments like radiation or chemotherapy, which often carry significant side effects. The nanoparticles are designed to be biocompatible and to clear from the body after their job is done, though long-term safety data are still needed.
While the results are encouraging, the researchers caution that the therapy has only been tested in mice. Human trials are required to determine whether the nanoparticles are safe and effective in patients, and to optimize the imaging and activation protocols. The team is currently working on scaling up production and conducting further preclinical studies to support a future clinical trial.
If successful, this technology could offer a new weapon against glioblastoma, which has seen little improvement in survival rates over the past decades. The ability to visualize and destroy hidden cancer cells in real time during surgery could significantly improve outcomes for patients facing this devastating disease. The study adds to a growing body of research exploring nanoparticles for cancer diagnosis and treatment, but it stands out for its combined imaging and therapeutic capabilities in a single agent.
